Technology

Gravitas Medical, Inc. Announces SECOND FDA Clearance for its Entarik System; Neonatal Patients to Benefit from Enteral Nutrition Innovation

Published

1 year ago

November 27, 2024

Gravitas Medical received NEONATAL FDA 510(k) clearance for the Entarik system, which aids in the placement of feeding tubes and continuously monitors feeding tube position, gastric and esophageal temperature, and gastrointestinal impedance and reflux.

BERKELEY, Calif., Nov. 27, 2024 /PRNewswire-PRWeb/ — Gravitas Medical, Inc. is pleased to announce that it received Neonatal 510(k) clearance from the U.S. Food and Drug Administration (FDA). This clearance allows Gravitas Medical to market its revolutionary Entarik technology to the US neonatal population.

“We are extremely pleased to announce that Gravitas Medical now has the ONLY smart enteral nutrition delivery system cleared for neonates and the ONLY EN solution with continuous monitoring”, says CEO Jorgen B Hansen. The Entarik System is designed for enteral feeding and to aid in the placement of the Entarik Enteral Feeding Tube into the stomach of neonatal patients requiring enteral feeding. The Entarik System also continuously monitors feeding tube position, gastric and esophageal temperature, and gastrointestinal impedance and reflux.

The co-founder & CTO Saheel Sutaria continues: “This is a huge milestone that will allow us to improve care in a vulnerable population where feeding tubes are essentially placed blind since x-ray radiation is avoided if possible, and many babies are underfed due to a lack of data. In addition, with clearance in neonates and adults, we can now build out a full portfolio for all ages in between.” He adds, “we would like to thank the visionary investigators at our clinical sites for their dedication to improving EN for neonates, as well as our hard-working team for making this happen.”

About Gravitas Medical

Gravitas Medical Inc. is a Silicon Valley-based medical device company committed to revolutionizing enteral feeding into enteral nutrition intelligence. By harnessing the power of technology, Gravitas Medical transforms gut-related information into actionable insights for caregivers. This approach enables better decision-making, improved patient outcomes, reduced hospital stays, and a decreased overall cost of care.

www.gravitasmedinc.com

Media Contact

Saheel Sutaria, Gravitas Medical, Inc., 1 6505166508, info@gravitasmedinc.com, https://www.gravitasmedinc.com/

View original content to download multimedia:https://www.prweb.com/releases/gravitas-medical-inc-announces-second-fda-clearance-for-its-entarik-system-neonatal-patients-to-benefit-from-enteral-nutrition-innovation-302316158.html

SOURCE Gravitas Medical, Inc.

Technology

IGCS International Announces Strategic Equity Investment by Lacks Enterprises

Published

59 minutes ago

April 22, 2026

DALLAS, April 22, 2026 /PRNewswire/ — IGCS International, a CVE-certified SDVOSB and leading provider of mission support and MRO supplies to the U.S. Department of Defense and federal agencies, today announced that Lacks Enterprises has acquired an equity stake in the company.

The strategic investment combines IGCS’s expertise in government supply chain, logistics, and MRO solutions with Lacks Enterprises’ advanced manufacturing capabilities, including electroplating, injection molding, composites, and testing for aerospace and defense.

“IGCS has built a strong track record supporting the Department of Defense… Partnering with Lacks Enterprises allows us to integrate cutting-edge manufacturing innovation into our offerings,” said Russ Spears, President of IGCS International.

Media Contact: Russ Spears, 214-733-7278, russ@igcsintl.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/igcs-international-announces-strategic-equity-investment-by-lacks-enterprises-302750824.html

SOURCE IGCS International

Technology

Shoulder Innovations to Report First Quarter 2026 Financial Results on May 13, 2026

Published

59 minutes ago

April 22, 2026

GRAND RAPIDS, Mich., April 22, 2026 /PRNewswire/ — Shoulder Innovations, Inc. (“Shoulder Innovations”) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the first quarter of 2026 after market close on Wednesday, May 13, 2026.

Management will host a conference call to discuss financial results beginning at 4:30 p.m. ET / 1:30 p.m. PT on May 13, 2026. Those interested in listening to the conference call may do so by dialing (877) 407-8216 for domestic callers or (412) 902-1015 for international callers and providing access code 13759613. A live and archived webcast of the event will be available in the “Investor Relations” section of the Shoulder Innovations website at https://ir.shoulderinnovations.com/.

About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations’ ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations’ ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.

Contact
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
ir@shoulderinnovations.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shoulder-innovations-to-report-first-quarter-2026-financial-results-on-may-13-2026-302750154.html

SOURCE Shoulder Innovations

Technology

Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026

Published

60 minutes ago

April 22, 2026

MADISON, Wis., April 22, 2026 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 6, 2026.

The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call’s conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (international), conference ID: 4178502.

A live webcast of the call will also be available from the Investor Relations section of the company’s website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the fourth quarter of fiscal 2026.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Investor and Media Contact
Steve Monroe
VP, Financial Planning & Analysis, Accuray
Investor.relations@accuray.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-to-report-third-quarter-fiscal-2026-financial-results-on-may-6-2026-302750641.html

SOURCE Accuray Incorporated